

**Supplemental Table S9.** Economic Benefit of Prescribing RDA DPP4 Inhibitors in Patients with Impaired Kidney Function per Year (2012 to 2018)

	2012	2013	2014	2015	2016	2017	2018
<b>CKD-EPI eGFR &lt;60 mL/min/1.73 m<sup>2</sup></b>							
Current	509,889.3	850,109.4	1,046,988.9	1,307,819.0	1,654,095.7	2,142,199.2	2,290,413.7
Model 1	-4,404.5 (-0.9)	-41,637.1 (-4.9)	-53,183.5 (-5.1)	-95,102.7 (-7.3)	-130,370.8 (-7.9)	-175,248.9 (-8.2)	-188,948.8 (-8.2)
Model 2	-5,936.2 (-1.2)	-70,981.7 (-8.3)	-100,744.0 (-9.6)	-177,907.5 (-13.6)	-270,351.1 (-16.3)	-395,496.9 (-18.5)	-443,065.1 (-19.3)
<b>CKD-EPI eGFR &lt;45 mL/min/1.73 m<sup>2</sup></b>							
Current	135,086.8	322,657.9	442,599.4	619,021.2	828,886.7	1,118,976.3	1,220,068.4
Model 1	-7,883.2 (-5.8)	-65,594.8 (-20.3)	-91,978.6 (-20.8)	-143,006.1 (-23.1)	-182,690.6 (-22.0)	-237,424.2 (-21.2)	-256,716.3 (-21.0)
Model 2	-9,428.1 (-7.0)	-94,362.8 (-29.2)	-146,974.0 (-33.2)	-234,824.2 (-37.9)	-331,860.0 (-40.0)	-466,122.3 (-41.7)	-519,758.6 (-42.6)
<b>CKD-EPI eGFR &lt;30 mL/min/1.73 m<sup>2</sup></b>							
Current	509,889.3	850,109.4	1,046,988.9	1,307,819.0	1,654,095.7	2,142,199.2	2,290,413.7
Model 1	-5,048.5 (-13.7)	-37,944.0 (-29.5)	-50,781.0 (-27.6)	-86,719.7 (-30.0)	-114,587.0 (-28.7)	-153,109.1 (-27.7)	-172,000.8 (-28.1)
Model 2	-5,776.8 (-15.7)	-53,444.8 (-41.5)	-80,461.0 (-43.7)	-140,635.3 (-48.6)	-203,515.5 (-51.0)	-293,740.8 (-53.1)	-336,532.4 (-55.0)

Values are expressed in US dollars (\$) indicating total annual cost savings, with percentages (%) in parentheses representing the relative reduction in costs.

RDA, renal dose-adjusted; DPP4, dipeptidyl peptidase-4; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.